Notice: Fall 2017 exams affected by natural disasters... More >

Expand/Collapse Close

ABIM knows that we have many physicians whose lives have been upended by recent natural disasters. If you live or work near an affected area, we understand that the weather may have impacted your ability to take your Fall 2017 exam as scheduled. We have developed a series of options to help you get through this process as smoothly as possible. If you have any questions, please call us at 1-800-441-ABIM (2246) or email request@abim.org.

American Board of Internal Medicine home page

MOC is a professionally determined standard that attests that an internist is staying current in knowledge and practice throughout his/her career.

Initial Certification indicates that physicians have met rigorous standards through intensive study, accredited training and evaluation and that they have the clinical judgment, skills and attitudes essential for the delivery of excellent patient care.

For more than 75 years, Certification by ABIM has stood for the highest standard in internal medicine and its 20 subspecialties.

Test and Policy Committee on Transplant Hepatology

Steven K. Herrine, MD, Chair

Dr. Herrine is Professor of Medicine and Vice Dean for Academic Affairs and Undergraduate Medical Education at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, Pennsylvania. He is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology.

Dr. Herrine serves as Program Director of the transplant hepatology fellowship and previously served as Medical Director of Liver Transplantation at Thomas Jefferson University Hospital. He currently serves as Chair of the American Board of Internal Medicine Test and Policy Committee on Transplant Hepatology. He previously served as Chair of the Membership and Mentorship Committee and the Training and Clinical Policy Committee of the American Association for the Study of Liver Disease (AASLD). He is a fellow of the American College of Physicians, the American Gastrointestinal Association and the AASLD.

Dr. Herrine received his bachelor's degree in mathematics and history from Oberlin College and his medical degree from Jefferson Medical College. After his residency at the Hospital of the University of Pennsylvania, he completed his fellowship training at Thomas Jefferson University Hospital.

As of January 2017, Dr. Herrine reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Thomas Jefferson University, from the following companies:

  • Bristol-Myers Squibb, for a trial of treatment of hepatitis C.
  • Gilead, for a trial of treatment of hepatitis C.
  • Galectin, for a trial of treatment of nonalcoholic steatohepatitis.

Work as an author or editor for following companies, with compensation as listed:

  • Clinical Liver Disease, receiving compensation as an editor.

Dr. Herrine serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Association for the Study of Liver Diseases, MOC Committee Member, without compensation.

Estella Alonso, MD

Dr. Alonso is board certified by the American Board of Pediatrics, which jointly develops the Transplant Hepatology certification exam with ABIM.

Bio coming soon.

View my board certification status via ABMS Website

As of January 2017, Dr. Alonso reported no external relationships.

Michael B. Fallon, MD

Bio coming soon.

As of January 2017, Dr. Fallon reported the following external relationships:

Funding for clinical trial expenses, staff, and salary support, paid to The University of Texas Health Science Center at Houston, from the following companies:

  • Bristol-Myers Squibb, funding for two clinical trials relating to hepatitis C.
  • Conatus, for a clinical trial relating to liver cirrhosis.
  • Eisai Co., funding for a clinical trial to evaluate avatrombopag for thrombocytopenia associated with liver disease prior to an elective procedure.
  • Intercept Pharmaceuticals, funding for two clinical trials to study the effect of obeticholic acid on clinical outcomes in primary biliary cirrhosis and nonalcoholic steatohepatitis.
  • Parexel International Incorporation, funding for a clinical trial relating to hepatitis C.
  • SC Liver Research Consortium, funding for two clinical trials relating to hepatitis B, hepatitis C and cirrhosis.
  • Tobira, funding for a trial relating to treatment of nonalcoholic steatohepatitis.

Maureen M. Jonas, MD

Dr. Jonas is Director of the Center for Childhood Liver Diseases at Boston Children's Hospital and Professor of Pediatrics at Harvard Medical School. She is board certified in both Pediatric Gastroenterology and Pediatric Transplant Hepatology by the American Board of Pediatrics. She is a fellow of the American Association for the Study of Liver Diseases (AASLD).

Dr. Jonas has been a staff physician in the Division of Pediatric Gastroenterology, Hepatology and Nutrition at Boston Children's Hospital since 1991. She was Medical Director of the Liver Transplant Program from 1991 to 2014, and Program Director for the Pediatric Transplant Hepatology Fellowship since 2010. She has been the Physician Quality Leader for the Pediatric Transplant Center since 2014. Prior to 1991, Dr. Jonas was in the Division of Pediatric Gastroenterology at the University of Miami Jackson Memorial Hospital, where she served as Medical Director of the Pediatric Liver Transplant Program.

She is a member of the American Board of Internal Medicine Test and Policy Committee on Transplant Hepatology. Dr. Jonas has served on several committees of national organizations, including the Clinical Committee, the Practice Guidelines Committee and the Ethics Committee of the AASLD; the Training and Education Committee and the Executive Council of the North American Society for Pediatric Gastroenterology Hepatology and Nutrition; and the Executive Committee of the Section on Pediatrics of the American Academy of Pediatrics.

Dr. Jonas received a bachelor's degree in biology from Tufts University, and her medical degree from the University of Miami. She completed both her pediatrics residency and pediatric gastroenterology fellowship at Boston Children's Hospital.

View my board certification status via ABMS Website

As of January 2017, Dr. Jonas reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Boston Children's Hospital, from the following companies:

  • AbbVie, providing funding for a clinical trial for treatment of hepatitis C in children.
  • Bristol-Myers Squibb, providing funding for randomized trials of entecavir for chronic hepatitis B in children.
  • Gilead Sciences, Inc., providing funding for two clinical trials of hepatitis C treatments in children.
  • Roche, providing funding for a trial of peginterferon for chronic hepatitis B in children.

Service on data and safety monitoring boards for the following company, with honoraria:

  • Gilead Sciences, Inc., serving as the chair of a data and safety monitoring board for a clinical trial of tenofovir for chronic hepatitis B in children.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following company, with honoraria:

  • AbbVie, consulting on design of new clinical trial for hepatitis C in children.

Dr. Jonas reported receiving a donation of transient elastography from Echosens for several research studies.

Work as an author or editor for following companies, with compensation as listed:

  • Springer, receiving royalties from sales of a monograph.
  • UpToDate, receiving annual royalties.

Hyung L. Kim-Schluger, MD

Dr. Kim-Schluger is board certified in Transplant Hepatology and Gastroenterology. She is the Associate Director of the Recanati/Miller Transplantation Institute and was named the Sydney J. Zweig Professor of Medicine.

Dr. Kim-Schluger's expertise is the management of liver transplant recipients, as well as on the natural course and treatment of hepatitis C. Among her research efforts have been studies that named to identify different treatment options for patients with hepatitis C virus infection, to better understand the course of hepatitis C after liver transplantation and to determine the best immunosuppressive drug regimens for liver transplant recipients. Dr. Kim-Schluger also has a special interest in the controversial issues and ethical dilemmas of organ allocation. She is a member of the American Board of Internal Medicine Test and Policy Committee on Transplant Hepatology.

She received her medical degree from the Columbia University College of Physicians and Surgeons. She completed an internship in internal medicine at the Beth Israel Deaconess Medical Center-Harvard Medical School and her residency in internal medicine at the Columbia-Presbyterian Medical Center. She completed her fellowship in gastroenterology at Columbia University College of Physicians and Surgeons and fellowship in hepatology at the Mount Sinai Hospital.

As of January 2017, Dr. Kim-Schluger reported no external relationships.

Anne M. Larson, MD

Bio coming soon.

As of January 2017, Dr. Larson reported the following external relationships:

Work as an author or editor for following company, with compensation as listed:

  • UpToDate, receiving compensation as an author.

Dr. Larson serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Association for the Study of Liver Diseases, Chair of Finance Committee, receiving reimbursement for travel expenses.

Hugo E. Vargas, MD

Bio coming soon.

As of January 2017, Dr. Vargas reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to the Mayo Clinic, from the following company:

  • Mallinckrodt Pharmaceuticals, for a trial for treatment of hepatorenal syndrome.

Service on data and safety monitoring boards for the following company, with compensation for travel expenses and honoraria:

  • TransMedics, for a graft preservation device in liver transplantation.

Dr. Vargas serves as faculty for continuing medical education on hepatitis C receiving honoraria from the Chronic Liver Disease Foundation, which receives support from educational grants from pharmaceutical companies.

Work as an author or editor for following companies, with compensation as listed:

  • American College of Gastroenterology, receiving compensation as Associate Editor for American Journal of Gastroenterology.
  • Mayo Clinic, receiving royalties for a textbook, paid to the Mayo Clinic.

Dr. Vargas serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Association for the Study of Liver Diseases, Chair of Ethics Committee, receiving reimbursement for travel expenses.

Funding for clinical trial expenses, staff and salary support, paid to the Mayo Clinic, from the following organizations:

  • National Institutes of Health, for a trial for treatment of hepatorenal syndrome.
  • National Institutes of Health & National Institute of Diabetes and Digestive and Kidney Diseases, for a trial of treatment of alcoholic hepatitis.

Kymberly D. Watt, MD

Dr. Watt is board certified in Gastroenterology and Transplant Hepatology. She is an Associate Professor of Medicine at Mayo Clinic in Rochester, Minnesota. Dr. Watt is the Medical Director of the liver transplant program for the William J. von Leibig Center for Transplantation and Clinical Regeneration at Mayo Clinic.

Dr. Watt previously practiced hepatology and liver transplantation at Dalhousie University, Halifax, Nova Scotia, Canada and assisted in restarting a liver transplant program in Atlantic Canada.

Dr. Watt is currently a committee member on the United Network for Organ Sharing Liver and Intestine Committee as well as the American Association for the Study of Liver Disease (AASLD) research committee, the International Liver Transplant Society education committee and the American Gastroenterological Association (AGA) nomination committee as well as serving as a women's representative on both AASLD and AGA committees. She is also a member of the American Board of Internal MedicineTest and Policy Committee on Transplant Hepatology.

Dr. Watt completed her bachelor's degree, medical degree, internal medicine residency and gastroenterology fellowship at the University of Manitoba and a transplant fellowship at the University of Nebraska Medical Center.

As of January 2017. Dr. Watt reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the Mayo Clinic, from the following companies:

  • Gilead Sciences, for four hepatitis C antiviral studies using sofosbuvir and ledipasvir.
  • Intercept Pharmaceuticals, for a trial of treatment of cirrhosis with obeticholic acid.